130 citations,
November 2017 in “Frontiers in Immunology” The conclusion is that Treg-targeted therapies have potential, but more knowledge of Treg biology is needed for effective treatments, including for cancer.
124 citations,
November 2000 in “The journal of investigative dermatology/Journal of investigative dermatology” PAD3 plays a key role in hair and skin protein structure and may be linked to skin diseases.
38 citations,
January 2017 in “PPAR Research” PPAR-γ helps control skin oil glands and inflammation, and its disruption can cause hair loss diseases.
38 citations,
January 2001 in “Neuroepidemiology” The current system can't fully test all combination treatments, so alternative methods and regulatory flexibility are needed.
26 citations,
October 2016 in “Case Reports in Dermatology” A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.
15 citations,
December 2021 in “Pharmaceutics” The study found key factors in the cause of hidradenitis suppurativa, its link to other diseases, and identified existing drugs that could potentially treat it.
14 citations,
November 2016 in “Annals of Internal Medicine” Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
12 citations,
May 2017 in “Pharmacology & therapeutics” Targeting immune tolerance issues in Alopecia Areata could restore hair growth and maintain remission.
5 citations,
May 2020 in “Journal of The American Academy of Dermatology” Hydroxychloroquine might help prevent COVID-19, but more research is needed.
4 citations,
July 1994 in “Clinics in Dermatology” Eosinophilia-myalgia syndrome, linked to contaminated L-tryptophan supplements, caused severe symptoms and some deaths, with long-term effects in survivors.
2 citations,
November 2023 in “Frontiers in microbiology” The health of the gut may be important in developing new ways to prevent, diagnose, and treat alopecia areata.
1 citations,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
July 2019 in “The European research journal” RDW can be a useful marker for inflammation in alopecia areata patients.
January 2016 in “Chemistry & Industry” Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
149 citations,
July 2002 in “Dermatologic clinics” Patients with certain skin symptoms and high ANA titers should be monitored for potential systemic lupus.
142 citations,
March 2019 in “Frontiers in Cellular Neuroscience” The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
116 citations,
February 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors help with skin conditions but need more research on dosing and safety.
109 citations,
November 2004 in “Lupus” The paper concludes that the 1982 criteria for diagnosing systemic lupus erythematosus need updating to improve accuracy and involve dermatologists in the process.
105 citations,
September 1995 in “Journal of The American Academy of Dermatology” Recombinant cytokine therapy can cause skin reactions ranging from mild to severe.
74 citations,
May 2016 in “Current opinion in pediatrics, with evaluated MEDLINE/Current opinion in pediatrics” Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.
72 citations,
February 2011 in “The American Journal of Dermatopathology” Anti-TNF therapy can cause a unique type of hair loss that may get better with topical treatments without stopping the therapy.
63 citations,
April 2018 in “Journal of the American Academy of Dermatology” Topical JAK inhibitors may help treat some skin conditions but need more research.
62 citations,
June 2015 in “The Journal of Dermatology” People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.
55 citations,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
42 citations,
June 2020 in “Seminars in Oncology” Sex hormones may affect COVID-19 severity, with men often faring worse, and targeting related pathways could offer treatment options.
41 citations,
June 2016 in “Reviews in endocrine and metabolic disorders” Hidradenitis suppurativa may be related to hormones and patients often have metabolic disorders; more research is needed to understand this connection.
36 citations,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
30 citations,
May 2016 in “Expert Opinion on Biological Therapy” New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
27 citations,
December 2015 in “Mayo Clinic Proceedings” The document concludes that lifestyle changes and medical treatments can significantly reduce symptoms of Hidradenitis Suppurativa, a chronic skin condition.